Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$507.42 USD

507.42
849,492

+1.08 (0.21%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut

Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.

    John Blank headshot

    Trade Tensions Begin to Escalate: Global Week Ahead

    Markets will be gradually informed by developments in U.S.-China trade tensions over the coming weeks.

      Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why

      Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.

        Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

        Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

          BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

          BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

            Ryan McQueeney headshot

            Anatomy of Success: Intuitive Surgical (ISRG)

            If investors had followed our model when it identified this futuristic healthcare technology manufacturer, they would have achieved massive profits.

              Here's Why You Should Invest in Intuitive Surgical Right Now

              Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.

                STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y

                Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.

                  Wright Medical (WMGI) Beats on Q1 Earnings, Keeps Guidance

                  Wright Medical's (WMGI) Q1 results solid; growth in upper and lower extremities segments encourages.

                    Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates

                    Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.

                      Penumbra (PEN) Q1 Earnings & Revenues Top Estimates, View Up

                      Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.

                        Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength

                        Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.

                          Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View

                          Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.

                            Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3

                            Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.

                              Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact

                              We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.

                                Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth

                                Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.

                                  Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y

                                  Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.

                                    DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View

                                    Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q1.

                                      PetMed (PETS) Q4 Earnings Top Estimates, Reorder Sales Solid

                                      PetMed (PETS) Q4 sales rise on increased reorders

                                        Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                                        Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                                          Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand

                                          Bruker's (BRKR) Q1 benefits from improved European revenues, rising year over year in high-single digits.

                                            ABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive

                                            ABIOMED (ABMD) gains on surging Impella revenues, number of regulatory approvals.

                                              Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View

                                              Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                                DENTSPLY (XRAY) Beats Q1 Earnings Estimates, Lowers View

                                                Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.

                                                  IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1

                                                  IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.